Influence of typical and atypical antipsychotics on neuropeptide Y-like immunoreactivity and NPY mRNA expression in rat striatum

Neuropeptides

Volumn 32, Issue 5, 1998, Pages 473-480

  Obuchowicz, E ^a,c   Turchan, J ^b  

^a UNIVERSITY OF SILESIA   (Poland)

^b POLISH ACADEMY OF SCIENCES   (Poland)

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROPEPTIDE Y; SULPIRIDE;

ANIMAL EXPERIMENT; ARTICLE; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG RECEPTOR BINDING; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; MESSENGER RNA SYNTHESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS REGULATION; RAT;

ANIMALIA;

EID: 0031770263     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0143-4179(98)90074-9     Document Type: Article

References (56)

1. Ebadi M, Srinivasan S K. Pathogenesis, prevention, and treatment of neuroleptic-induced movement disorders. Pharmacol Rev 1995; 47: 575-604.
2. Heilig M, Widerlöv E. Neurobiology and clinical aspects of neuropeptide Y. Crit Rev Neurobiol 1995; 9: 115-136.
3. Blomqvist A G, Herzog H. Y-receptor subtypes-how many more? Trends Neurosci 1997; 20: 294-298.
4. De Quidt M E, Emson P C. Distribution of neuropeptide Y-like immunoreactivity in the rat central nervous system I. Radioimunnoassay and Chromatographic characterisation. Neuroscience, 1986; 18: 527-543.
5. 2 receptor radioligands. Synapse 1996; 22: 139-158.
6. Beal M F, Chattha G K, Martin J B. A comparison of regional somatostatin and neuropepitide Y distribution in rat striatum and brain. Brain Res 1986; 377: 240-245.
7. Houdeau E, Boyer P-A. In situ hybridization study of neuropeptide Y neurons in the rat brain and pelvic paracervical ganglion. Cell Tissue Res 1994; 277: 579-586.
8. Christie M J, Beart P M, Jarrott B, Maccarrone C. Distribution of neuropeptide Y immunoreactivity in the rat basal ganglia: effects of excitotoxin lesions to caudate-putamen. Neurosci Lett 1986; 63: 305-309.
9. Figueredo-Cardenas G, Morello M, Sancesario G et al. Colocalization of somatostatin, neuropeptide Y, neuronal nitric oxide synthase and NADPH-diaphorase in striatal interneurons in rats. Brain Res 1996; 735: 317-324.
10. Aoki C, Pickel V M. Neuropeptide Y in cortex and striatum. Ultrastructural distribution and coexistence with classical neurotransmitters and neuropeptides. Ann N Y Acad Sci 1990; 611: 186-205.
11. Vuillet J, Kerkerian L, Kachidian P et al. Ultrastructural correlates of functional relationships between nigral dopaminergic or cortical afferent fibers and neuropeptide Y containing neurons in the rat striatum. Neurosci Lett 1989; 100: 99-104.
12. Kubota Y, Inagaki S, Kito S et al. Neuropeptide Y-immunoreactive neurons receive synaptic inputs from dopaminergic axon terminals in the rat neostriatum. Brain Res 1988; 458: 389-393.
13. Vuillet J, Dimova R, Nieoullon A, Kerkerian-Le Goff L. Ultrastructural relationships between choline acetyltransferase-and neuropeptide Y-containing neurons in the rat striatum. Neuroscience 1992; 46: 351-360.
14. Kerkerian L, Salin P, Nieoullon A. Pharmacological characterization of dopaminergic influence on expression of neuropeptide Y immunoreactivity by rat striatal neurons. Neuroscience 1988; 26: 809-817
15. 13-36 on the brain monoaminergic systems of the rat. J Neural Transm [GenSect] 1990; 79: 193-208.
16. Lindefors N, Brene S, Herrera-Marschitz M, Persson H. Regulation of neuropeptide Y gene expression in rat brain. Ann N Y Acad Sci 1990; 611: 175-185.
17. 2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin. Brain Res 1992; 581: 261-268.
18. Kerkerian-Le Goff L, Forni C, Samuel D et al. Intracerebroventricular administration of neuropeptide Y affects parameters of dopamine, glutamate and GABA activities in the rat striatum. Brain Res Bull 1992; 28: 187-193.
19. Midgley L P, Wagstaff J D, Singh N A et al. Dynamic dopaminergic regulation of neuropeptide Y systems in discrete striatal and accumbens regions. Eur J Pharmacol 1994; 251: 191-199.
20. Heilig M, Wahlestedt C, Widerlöv E. Neuropeptide Y (NPY)-induced suppression of activity in the rat: evidence for NPY receptor heterogeneity and for interaction with alphaadrenoceptors. Eur J Pharmacol 1988; 157: 205-213.
21. Jolicouer F B, Michaud J N, Rivest R et al. Neurobehavioral profile of neuropeptide Y. Brain Res Bull 1991; 26: 265-268.
22. Moore E, Merali Z, Beninger RJ. Neuropeptide Y: intrastriatal injections produce contralateral circling that is blocked by a dopamine antagonist in rats. Pharmacol Biochem Behav 1994; 48: 681-688.
23. Miyake M, Iguchi K, Okamura H et al. Effect of haloperidol on immunoreactive neuropeptide Y in rat cerebral cortex and basal ganglia. Brain Res Bull 1990; 25: 263-266.
24. Ellenbroek B A. Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs. Pharmacol Ther 1993; 57: 1-78.
25. Ruggieri S, De Pandis M F, Bonamartini A et al. Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson's disease. Clinical Neuropharmacol 1997; 20: 204-209.
26. 4 receptor. J Pharmacol Exp Ther, 1997; 283: 636-647.
27. Horn A S, Cuello A C, Miller R J. Dopamine in the mesolimbic system of the rat brain: endogenous levels and the effects of drugs on the uptake mechanism and stimulation of adenylate cyclase activity. J Neurochem 1974; 22: 265-270.
28. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates, 2nd edn., Academic Press, Sydney.
29. Obuchowicz E. Long-term treatment with chlorpromazine and haloperidol but not with sulpiride and clozapine markedly elevates neuropeptide Y-like immunoreactivity in the rat hypothalamus. Neuropeptides 1996; 30: 471-478.
30. Young III W S, Bonner T I, Brann M R. Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNA in the rat forebrain. Proc Natl Acad Sci 1986; 83: 9827-9831.
31. 2 receptors. Psychopharmacology 1993; 112: S40-S54.
32. Ashby C R Jr, Wang R Y. Pharmacological actions of the atypical antipsychotic drug clozapine: a review. Synapse 1996; 24: 349-394.
33. Angulo J A, Cadet J L, McEwen B S. Effect of typical and atypical neuroleptic treatment on protachykinin mRNA levels in the striatum of the rat. Neurosci Lett 1990; 113: 217-221.
34. Humpel C, Knaus G A, Auer B et al. Effects of haloperidol and clozapine on preprotachykinin-A messenger RNA, tachykinin tissue levels, release and neurokinin-1 receptors in the striatonigral systems. Synapse 1990; 6: 1-9.
35. Salin P, Mercugliano M, Chesselet M F. Differential effects of chronic treatment with haloperidol and clozapine on the level of preprosomatostatin mRNA in the rat striatum, nucleus accumbens, and frontal cortex of the rat. Cell Mol Neurobiol 1990; 10: 127-144.
36. Jaber M, Tison F, Fournier M C, Bloch B. Differential influence of haloperidol and sulpiride on dopamine receptors and peptide mRNA levels in the rat striatum and pituitary. Mol Brain Res 1994; 23: 14-20.
37. Chiodo L A, Bunney B S. Population response of midbrain dopaminergic neurons to neuroleptics: further studies on time course and nondopaminergic neuronal influences. J Neurosci 1987; 7: 629-633.
38. Chang W H, Chen T Y, Hu W H, Yeh E K. Dose-response curves of homovanillic acid in pre-frontal cortex and caudate following antipsychotic drugs: relation to clinical potencies. Psychopharmacology-Berl 1988; 95: 459-462.
39. Patterson T A, Schenk J O. Effects of acute and chronic systemic administration of some typical antipsychotic drugs on turnover of dopamine and potassium ion-induced release of dopamine in the striatum of the rat in vivo. Neuropharmacology 1991; 30: 943-952.
40. Scatton B, Worms P, Zivkovic B et al. On the neuropharmacological spectra of 'classical' (haloperidol) and 'atypical' (benzamide dervatives) neuroleptics. In: Spano P F, Trabucchi M, Corsini G U, Gessa G L, eds. Sulpiride and Other Benzamides - Experimental and Clinical Pharmacology. Italian Brain Research Foundation Press-Milan 1979; 53-66.
41. Motohashi N, Takashima M, Mataga N et al. Effects of sulpiride and oxypertine on the dopaminergic system in the rat striatum. Neuropsychobiology 1992; 25: 29-33.
42. Pages N, Orosco M, Fournier G et al. The effects of chronic administration of morphine on the levels of brain and adrenal catecholamines and neuropeptide Y in rats. Gen Pharmacol 1991; 22: 943-947.
43. Pages N, Orosco M, Rouch C et al. Brain and adrenal monoamines and neuropeptide Y in codeine tolerant rats. Gen Pharmacol 1992; 23: 159-163.
44. Tatsuoka Y, Riskind P N, Beal M F, Martin J B. The effect of amphetamine on the in vivo release of dopamine, somatostatin and neuropeptide Y from caudate nucleus. Brain Res 1987; 411: 200-203.
45. Karoum F, Chrapusta S J, Brinjak R et al. Regional effects of amphetamine, cocaine, nomifensine and GBR 12909 on the dynamics of dopamine release and metabolism in the rat brain. Brit J Pharmacol 1994; 113: 1391-1399.
46. Blaha C D, Lane R F. Chronic treatment with classical and atypical antipsychotic drugs differentially decreases dopamine release in striatum and nucleus accumbens in vivo. Neurosci Lett 1987; 78: 199-204.
47. Bendotti C, Tarizzo G, Fumagalli F et al. Increased expression of preproneuropeptide Y and preprosomatostatin mRNA in the striatum after selective serotoninergic lesions in rats. Neurosci Lett 1993; 160: 197-200.
48. Kilts C D, Anderson C M, Bissette G et al. Differential effects of antipsychotic drugs on the neurotensin concentration of discrete rat brain nuclei. Biochem Pharmacol 1988; 37: 1547-1554.
49. Bolden-Watson C, Watson M A, Murray K D et al. Haloperidol but not clozapine increases neurotensin receptor mRNA levels in rat substantia nigra. J Neurochem 1993; 61: 1141-1143.
50. 5-enkephalin-like immunoreactivity in rats following chronic treatment with haloperidol but not with clozapine: implications for the pathogenesis of neuroleptic-induced movement disorders. Exp Neurol 1992; 117: 17-27.
51. Prosser E S, Pruthi R, Csernansky J G. Differences in the time course of dopaminergic supersensitivity following chronic administration of haloperidol, molindone, or sulpiride. Psychopharmacology-Berl 1989; 99: 109-116.
52. 3 receptors in rat brain. Psychopharmacology 1996; 128: 362-370.
53. Le Moine C, Normand E, Bloch B. Phenotypical characterization of the striatal neurons expressing the Dl dopamine receptor gene. Proc Natl Acad Sci USA 1991; 88: 4205-4209.
54. Anderson K D, Reiner A. Immunohistochemical localization of DARPP-32 in striatal projection neurons and striatal interneurons: implications for the localization of D-1 like dopamine receptors on different types of striatal neurons. Brain Res 1991; 568: 235-243.
55. Beal M F, Frank R C, Ellison D W, Martin J B. The effect of neuropeptide Y on striatal catecholamines. Neurosci Lett 1986; 71: 118-123.
56. Drumheller A, Bouali S M, Fournier A et al. Neurochemical effects of neuropeptide Y (NPY) and NPY 2-36. Neuropeptides 1994; 27: 291-296.